Leukaemia Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People who have been recently diagnosed with a type of blood cancer called AML (acute myeloid leukaemia) for the first time, with the diagnosis confirmed within 28 days of symptoms starting. A prior treatment to reduce white blood cell counts (such as hydroxyurea) is permitted.
- People aged 75 or older who are not suitable for the standard intensive chemotherapy used for AML.
- People aged between 60 and 74 who are not suitable for standard intensive chemotherapy, and who also have at least one of the following health conditions: reduced ability to carry out daily activities due to their illness; heart failure requiring treatment, reduced heart pumping function, or stable chest pain (angina); reduced lung function based on breathing tests; reduced kidney function within a specific range; liver damage (not caused by AML) with elevated bilirubin levels within a specific range; or another health condition that a doctor has determined makes standard chemotherapy unsuitable.
- People whose condition makes them suitable for the current standard treatment for AML in this setting, which is a combination of two medicines called venetoclax and a hypomethylating agent (confirm with trial site).
- People who have voluntarily signed and dated a consent form that has been approved by the relevant authorities.
- People already taking part in another clinical study may still be eligible, provided that other study does not conflict with this one (confirm with trial site).
Who may not be able to join:
- People whose blood white cell count is above 25 G/L at the time of enrolment.
- People who have previously received any cancer treatment — including medicines, surgery, or radiotherapy — for AML, any other blood cancer, or any other cancer within the last two years.
- People whose AML has spread to the brain or spinal fluid, or who have a specific subtype of AML called promyelocytic leukaemia (AML-M3).
- People with a serious uncontrolled illness at the time of enrolment, such as an active infection requiring treatment, uncontrolled heart failure, unstable chest pain (angina), a heart rhythm problem, or a mental health condition or substance dependency that could affect the ability to follow the study requirements.
- People who have a known serious allergic reaction to any of the medicines used in this trial.
- People who have taken certain medicines or foods known to strongly affect how the body processes drugs — including grapefruit or Seville oranges — within the 7 days before starting treatment.
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Pierre-Marie Morice, PharmD, PhD, University Teaching Hospital of Caen
Phone: +33231272107
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Comparison of mean plasma residual concentration of venetoclax
Can't join this trial?
Data last synced from ClinicalTrials.gov: 16 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.